Delving into the Latest Updates on Hangzhou Bolin Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Hangzhou Bolin Pharmaceutical Technology Co., Ltd was established in April 2021 by a team of scientists with extensive experience in siRNA drug development. The company is dedicated to developing a new generation of siRNA drugs to provide urgently needed and improved treatment options for patients worldwide. The Bolin Pharmaceutical team reportedly has years of professional experience in all aspects of RNAi drug development, including nucleotide sequence design, chemical modification, GalNAc delivery technology, extracellular liver targeting delivery technology, oligonucleotide synthesis, and CMC, establishing a comprehensive nucleic acid drug development platform.

Tags

Cardiovascular Diseases

Congenital Disorders

Immune System Diseases

siRNA

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Infectious Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

siRNA	4

Top 5 Target	Count

AGT(Angiotensinogen)	1
HBV RNA	1

本研究的主要目的是评估中国健康受试者单次皮下给药BW-00163 的安全性和耐受性。本研究的次要目的是评估BW-00163 及其代谢物的药代动力学（PK）及评估BW-00163 对血清血管紧张素原（AGT）水平的药效学（PD）影响本研究的探索目的是评估BW-00163 对收缩压（SBP）和舒张压（DBP）的影响、评估BW-00163 对肾素-血管紧张素-醛固酮系统（RAAS）生物标志物的影响及评估BW-00163 的免疫原性

[Translation]

The primary objective of this study is to evaluate the safety and tolerability of a single subcutaneous administration of BW-00163 in healthy Chinese subjects. The secondary objectives of this study are to evaluate the pharmacokinetics (PK) of BW-00163 and its metabolites and to evaluate the pharmacodynamic (PD) effects of BW-00163 on serum angiotensinogen (AGT) levels The exploratory objectives of this study are to evaluate the effects of BW-00163 on systolic blood pressure (SBP) and diastolic blood pressure (DBP), to evaluate the effects of BW-00163 on renin-angiotensin-aldosterone system (RAAS) biomarkers and to evaluate the immunogenicity of BW-00163

Start Date21 Nov 2023

Sponsor / Collaborator

Hangzhou Bolin Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Hangzhou Bolin Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Hangzhou Bolin Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Hangzhou Bolin Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Hangzhou Bolin Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

3

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BW-00112	Dyslipidemias More	Phase 2
BW-20805	Hereditary Angioedema More	Phase 1
BW-20507 ( HBV RNA )	Hepatitis B, Chronic More	Phase 1
BW-00163 ( AGT )	Hypertension More	Phase 1